louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01898780: Horizontal Mattress vs. Interrupted Suture in Surgical Techniques of Pancreaticojejunostomy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Patients Who Undergo Pancreatoduodenectomy
Lead sponsor: Wakayama Medical University
Sponsor class: OTHER
First posted: 2013-07-12
Enrollment: 190
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to verify that the frequency of pancreatic fistula (ISGPF grade B and C) in horizontal mattress suture are lower than in interrupted suture during pancreaticojejunostomy in pancreatoduodenectomy by randomized clinical trial.


Eligibility criteria: Inclusion Criteria:

Patients from whom we obtained written informed consent of this study

Exclusion Criteria:

* Patients with severe ischemic cardiac disease
* Patients with severe liver damage
* Patients requiring oxygen administration due to interstitial pneumonia or pulmonary fibrosis
* Patients requiring dialysis treatment due to chronic renal failure
* Patients who are considered as inappropriate by attending physician

Primary outcomes:
measure: The frequency of pancreatic fistula including ISGPF grade B and C
timeFrame: Ninety days after operation
Secondary outcomes:
measure: The rates of postoperative complications
timeFrame: Ninety days after operation
Other outcomes:
Locations:
city: Wakayama
country: Japan
facility: Second Department of Surgery, Wakayama Medical University
Study officials:
References:
citation: Hirono S, Kawai M, Okada KI, Miyazawa M, Kitahata Y, Hayami S, Ueno M, Yamaue H. Modified Blumgart Mattress Suture Versus Conventional Interrupted Suture in Pancreaticojejunostomy During Pancreaticoduodenectomy: Randomized Controlled Trial. Ann Surg. 2019 Feb;269(2):243-251. doi: 10.1097/SLA.0000000000002802.
Clinical trial NCT05637580: Pathological Tumor and Lymph Node Responses After Neoadjuvant Immunochemotherapy in Initially-unresectable NSCLC
Official title: Real-world Analysis of Pathological Tumor and Lymph Node Responses After Neoadjuvant Immunochemotherapy in Initially-unresectable Non-small Cell Lung Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Non Small Cell Lung Cancer
Immunotherapy
Chemotherapy
Tumour, Residual
Lead sponsor: Guangdong Provincial People's Hospital
Sponsor class: OTHER
First posted: 2022-12-05
Enrollment: 110
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with stage II-III NSCLC who received neoadjuvant immunochemotherapy (time) in Guangdong Provincial People's Hospital were eligible for this study. We also included early-stage NSCLC patients who were unsuitable or unable to tolerate surgery after first evaluation. Eligible patients were 18 years of age or older, had a karnofsky performance status (KPS) score of 100 or 90 (on a scale from 0 to 100 with higher score indicating better ability to carry out daily activities). Patients with distant tumor metastasis or with known ALK translocations or EGFR mutations were excluded.

Brief summary: This is a real-world study with the largest sample size investigating the pathological tumor and lymph node responses to neoadjuvant immunochemotherapy in non-small cell lung cancer to date. Patients with initially unresectable NSCLC underwent immunochemotherapy and response to treatment was assessed after every two treatment cycles. Clinicopathologic features of patients including epidemiological data, clinical manifestations, operation strategies, pathological findings, and prognostic information were recorded and evaluated.


Eligibility criteria: Inclusion Criteria:

* Patients with stage III NSCLC who received neoadjuvant immunochemotherapy.
* early-stage NSCLC patients who were initially unresectable.
* 18 years of age or older.
* Karnofsky performance status (KPS) score of 100 or 90.

Exclusion Criteria:

* Patients with stage IV NSCLC
* Patients with known ALK translocations or EGFR mutations.
* Karnofsky performance status (KPS) score \<90.

Primary outcomes:
measure: Event-free survival
timeFrame: At least one year
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Guangdong Provincial People's Hospital
state: Guangdong
Study officials:
affiliation: Guangdong Provincial People's Hospital
name: Guibin Qiao, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT02486380: Toffee Full Face and Toffee Nasal Mask Evaluation in Obesity Hypoventilation Syndrome (NZ)
Official title: Toffee Full Face and Toffee Nasal Mask Evaluation in Obesity Hypoventilation Syndrome (NZ)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Obesity Hypoventilation Syndrome
Lead sponsor: Fisher and Paykel Healthcare
Sponsor class: INDUSTRY
First posted: 2015-07-01
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This investigation is to evaluate the performance, comfort and ease of use of the Toffee full face and toffee nasal mask masks amongst Obesity Hypoventilation Syndrome (OHS) patients in an overnight study.

Detailed description: Up to 20 OHS patients who currently use a full face mask or a nasal mask will be recruited. They will be issued a F\&P Toffee Full face (if they are existing full face users) or F\&P Toffee Nasal (if they are existing nasal users) for an overnight polysomnography.

Eligibility criteria: Inclusion Criteria:

* Aged 18+
* Diagnosed with OHS by a practicing physician
* Existing full face mask user or a nasal mask user
* Prescribed PAP therapy (Bi-Level or CPAP)

Exclusion Criteria:

* Inability to give informed consent
* Pregnant or think they may be pregnant
* Anatomical or physiological conditions making PAP therapy inappropriate
* Patients requiring supplemental oxygen with their PAP device
* Patients who are in a coma or decreased level of consciousness
* Existing Toffee full face and Toffee nasal mask users
* No arterial PCO2 value from their medical records

Primary outcomes:
measure: Objective Leak data
timeFrame: 1 night
Secondary outcomes:
measure: Subjective measurement of Leak
timeFrame: 1 night
measure: Comfort
timeFrame: 1 night
measure: Ease of use
timeFrame: 1 night
measure: Sleep efficiency
timeFrame: 1 night
measure: Wake after Sleep Onset (WASO)
timeFrame: 1 night
measure: Arousal Index (AI)
timeFrame: 1 night
Other outcomes:
Locations:
city: Auckland
country: New Zealand
facility: Fisher & Paykel Healthcare
Study officials:
affiliation: Fisher & Paykel Healthcare
name: Bhavi Ogra, BSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03231462: Impact of Perioperative Physical Activity on Postoperative Pulmonary Complications and Quality of Life Among Esophageal Cancer Patients
Official title: Impact of Perioperative Physical Activity on Postoperative Pulmonary Complications and Quality of Life Among Esophageal Cancer Patients: A Prospective Cohort Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Esophageal Neoplasms
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
First posted: 2017-07-27
Enrollment: 180
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients who are diagnosed with eshophageal cancer and scheduled to receive curative esophagectomy at a single cancer hospital in Seoul, Korea

Brief summary: This prospective cohort study examines the impact of perioperative physical activity on postoperative pulmonary complications among esophageal cancer patients.


Eligibility criteria: Inclusion Criteria:

* Patients who are diagnosed with esophageal cancer and scheduled to receive curative esophagectomy
* Patients who are able to read and understand the questionnaire
* Patients who are able to communicate with research personnel
* Patients who recognize the purpose of this study and provide written informed consent
* Patients without treatment for psychiatric disease

Exclusion Criteria:

* Patients who have difficulty for walking
* Patients with history of other cancer in the last 3 years
* Patients with neoadjuvant chemotherapy and/or radiation therapy
* Patients with recurrent esophageal cancer
* Patients with multiple cancer
* Foreigner or overseas patients who were not able to regularly participate this study

Primary outcomes:
measure: Pulmonary complications
timeFrame: Within 30 days after surgery
Secondary outcomes:
measure: The change of quality of life
timeFrame: Before surgery(baseline), and 1, 6, 12, 24, 36, 48, and 60 months after surgery
measure: The change of symptom
timeFrame: Before surgery(baseline), and 1, 6, 12, 24, 36, 48, and 60 months after surgery
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
Study officials:
affiliation: Samsung Medical Center
name: Young Mog Shim, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06108362: Effect of Terlipressin on the Incidence of Early Postoperative Acute Kidney Injury in Liver Transplantation Patients
Official title: Effect of Intraoperative Terlipressin on the Incidence of Early Postoperative Acute Kidney Injury in Liver Transplantation Patients: a Randomized, Double-blind, Placebo-controlled Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: Acute Kidney Injury
Liver Transplant; Complications
Keywords: terlipressin
Liver Transplant
Lead sponsor: Beijing Tsinghua Chang Gung Hospital
Sponsor class: OTHER
First posted: 2023-10-31
Enrollment: 104
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to evaluate the effect of intraoperative terlipressin on the incidence of early postoperative acute kidney injury in deceased doner liver transplantation. Patients were randomly divided into experimental group and control group by numerical randomization table. The experimental group was injected with terlipressin perioperative and the control group was injected with placebo

Detailed description: acute kidney injury is a relatively common complication in patients with liver transplantation. Most centers have established prediction models for acute kidney injury after liver transplantation, but the incidence cannot be reduced through perioperative anesthesia management. As an vasopressin receptor agonist, terlipressin can increase blood pressure and improve kidney perfusion at the same time, and perioperative application may reduce the incidence of postoperative acute kidney injury

Eligibility criteria: Inclusion Criteria:

* 1) Patients who plan to undergo liver transplantation in our hospital 2) Patients or family members sign informed consent

Exclusion Criteria:

* Patients \<18 years old;② Patients undergoing autologous liver transplantation or combined transplantation;③ Patients with lower extremity artery stenosis;(4) Patients with severe heart disease、lung disease、kidney disease;⑤ Patients with severe lung disease;⑥ Patients who used renal replacement therapy before surgery;⑦ the depth of one kidney from the body surface is greater than 4cm;⑧ Patients treated with terlipressin within 2 weeks before surgery⑨ Patients allergic to terlipressin.

Primary outcomes:
measure: Incidence of acute kidney injury after liver transplantation
timeFrame: in 7 days
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Tsinghua Chang Gung Hospital
state: Beijing
Study officials:
affiliation: department of anesthesia
name: Huan Zhang, Doctor
role: STUDY_CHAIR
References:
Clinical trial NCT04661462: Health After Covid-19 in Tyrol
Official title: Health After COVID-19 in the European Region Tyrol - South Tyrol
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: COVID-19
Keywords: long term sequelae
Lead sponsor: Medical University Innsbruck
Sponsor class: OTHER
Collaborators: name: Claudiana Landesfachhochschule
First posted: 2020-12-10
Enrollment: 1000
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: voluntary participation of probands after COVID-19, resident in Tyrol, Austria, with access to online survey;

Brief summary: The aim of the regional online questionnaire is to better understand the pattern of acute infection and the time of recovery of various symptoms.

Detailed description: The ongoing COVID-19 pandemic considerably increases the demand for healthcare and raises concerns on longterm disease outcome. Accordingly, to increase the knowledge on recovery from symptoms of acute infection and longterm health effects, a regional COVID-19 online survey on the health-status after infection will be performed.

This cross-sectional anonymous online survey is initiated and conducted by an interdisciplinary study team of the Medical University of Innsbruck, Austria.

For each participant, demographic characteristics (e.g. age, gender, district affiliation, profession), medical history (presence of comorbidities, medication), diagnosis of COVID-19, symptoms and their duration, treatments and special conditions will be collected.

The aim of the survey is to better understand the pattern of acute infection and the time of recovery of various symptoms.

The anonymous online survey is open to individuals after COVID-19 infection (proven by SARS-Cov-2 positive PCR or antibody test) over the age of 16 and living in Tyrol (Western-Austria).

The survey takes around 30 minutes to complete.

Eligibility criteria: Inclusion Criteria:

* status post COVID-19 infection, defined by a positive SARS-Cov-2 PCR or antibody test
* age ≥ 16years
* resident in Tyrol (Austria)

Exclusion Criteria:

Primary outcomes:
measure: Population based data on spectrum and recovery from COVID-19 symptoms
timeFrame: two weeks after infection
measure: Population based data on spectrum and recovery from COVID-19 symptoms
timeFrame: up to 24 weeks
measure: Predictors of recovery.
timeFrame: up to 24 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Innsbruck
country: Austria
facility: Medizinische Universität Innsbruck
state: Tyrol
Study officials:
References:
citation: Hufner K, Tymoszuk P, Ausserhofer D, Sahanic S, Pizzini A, Rass V, Galffy M, Bohm A, Kurz K, Sonnweber T, Tancevski I, Kiechl S, Huber A, Plagg B, Wiedermann CJ, Bellmann-Weiler R, Bachler H, Weiss G, Piccoliori G, Helbok R, Loeffler-Ragg J, Sperner-Unterweger B. Who Is at Risk of Poor Mental Health Following Coronavirus Disease-19 Outpatient Management? Front Med (Lausanne). 2022 Mar 14;9:792881. doi: 10.3389/fmed.2022.792881. eCollection 2022.
Clinical trial NCT00000262: Effects of Combined Sevoflurane and Nitrous Oxide Inhalation - 14
Official title: Effects of Combined Sevoflurane and Nitrous Oxide Inhalation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Opioid-Related Disorders
Substance-Related Disorders
Keywords: nitrous oxide
sevoflurane
drug interaction
subjective effects
analgesia
healthy volunteers
Lead sponsor: University of Chicago
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 1999-09-21
Enrollment: 20
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the effects of combined sevoflurane and nitrous oxide inhalation on mood, psychomotor performance, and the pain response in humans.


Eligibility criteria: Please contact site for information.

Primary outcomes:
measure: Pain intensity, pain bothersomeness
timeFrame: During inhalation
measure: Mood
timeFrame: During inhalation
measure: Psychomotor performance
timeFrame: During inhalation
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: University of Chicago, Anesthesia & Critical Care
state: Illinois
Study officials:
affiliation: University of Chicago
name: James Zacny, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04693962: FGF23 as a Marker of Acute Kidney Injury
Official title: Fibroblast Growth Factor-23 as a Marker of Acute Kidney Injury After Partial Nephrectomy
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Acute Kidney Injury
Kidney Ischemia
Keywords: Acute kidney injury
Creatinine
Fibroblast Growth Factor-23
Lead sponsor: University of Chile
Sponsor class: OTHER
First posted: 2021-01-05
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients with a diagnose that requires any of three surgerys: Partial Nephrectomy, Hemicolectomy, Nephrolithotomy

Brief summary: A partial nephrectomy (PN) preserves renal parenchyma with a proper oncology outcome. PN is performed during transitory ischemia to avoid massive bleeding during tumor resection. Nevertheless, the transitory ischemia might cause an acute kidney injury(AKI). AKI diagnose is based on the increase in plasma creatinine concentration and a decrease in urine output. However, both plasma creatinine concentration and diuresis are useful for the diagnose, but not in the detection of the risk patients. Therefore, there is considerable interest to find a biomarkers of kidney injury that allow clinicians to predict the development of AKI. Hence, we propose Fibroblastic Growth Factor-23 (FGF23) as a novel early biomarker to detect patients in risk to develop postoperative AKI after a PN.

We will conduct an observational and prospective study in three different groups of patients: PN gropup, patients who underwent PN with a transient and controlled renal ischemia injury using a renal artery clamping; Hemicolectomy (HC) group, patients as non-renal ischemia surgery controls, with similar demographic characteristics, but submitted to HC; and Nephrolithotomy (NL) group, patients who underwent NL, as a control of kidney surgery with physical injury.

In each patient, a time curve of plasmatic creatinine, blood urea nitrogen (BUN), and FGF23 were measure.

Our study aims to describe the role of FGF23 as an early biomarker of AKI after PN, where patients are exposed to a controlled ischemic injury.


Eligibility criteria: Inclusion Criteria:

* American Society of Anesthesiology physical status (ASA) I or II.
* Normal preoperative plasma creatinine level
* Baseline estimated glomerular filtration rate (eGFR) \> 60 ml/min per 1.73 m2.

Exclusion Criteria:

* History of chronic kidney disease
* Anemia
* Alterations in the parathormone or vitamin D axis
* Pregnant women
* Subjects with concomitant use of nephrotoxic drugs.

Primary outcomes:
measure: Acute Kidney Injury
timeFrame: 72 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Santiago
country: Chile
facility: Hospital Clinic Universidad de Chile
Study officials:
References:
Clinical trial NCT06339762: Self-Compassion Training Given to Relatives of Patients in Palliative Care
Official title: ''Invitation to Self-Compassion: Reshaping the Burden of Care in the Light of Self-Compassion Training Given to Relatives of Patients in Palliative Care.''
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Self-Compassion Training
Lead sponsor: Firat University
Sponsor class: OTHER
First posted: 2024-04-01
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The concept of self-compassion is a concept that has been frequently the subject of research lately and has gained importance along with positive psychology. It is also referred to as self-understanding and self-compassion in the literature. The concept of self-compassion used in our study represents the concept of self-compassion in its original form as used in foreign sources. Compassion is classified according to the source to which it is directed or received. It is suggested that there are three different flows: the feeling of compassion that the individual directs from himself to others, the feeling of compassion he receives from others, and the feeling of compassion that he directs directly to his own self. It means showing oneself the same compassion and understanding one does to others, accepting and being open to one's own pain, and being accepting of oneself without being judgmental. Individuals with self-compassion believe that the difficulties, flaws and shortcomings they experience are normal. At the same time, they are aware that being human has characteristics and that everyone can experience these situations. Individuals may be less compassionate towards themselves than they are towards others. Individuals with self-compassion are as understanding, forgiving and loving towards themselves as they are towards other people.


Eligibility criteria: Inclusion Criteria:

* Being an inpatient in the Palliative unit of Erzurum City Center City Hospital
* Not having attended self-compassion training before
* The patient's relatives do not have any obstacle to communication
* Participants who gave informed consent to participate in the study.

Exclusion Criteria:

* Relatives of patients who do not agree to participate in the research,
* The participant must have attended self-compassion training before,
* People have a condition that prevents communication
* The occurrence of a physical or psychological problem in people during the research process
* Patient's relatives want to leave before completing the training

Primary outcomes:
measure: Self-Compassion Scale:
timeFrame: 4 week
measure: Care Burden Scale:
timeFrame: 4 week
Secondary outcomes:
Other outcomes:
Locations:
city: Elazığ
country: Turkey
facility: Fırat university
state: Center
Study officials:
References: